Medicure Inc. (CVE:MPH – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$1.35 and traded as high as C$1.55. Medicure shares last traded at C$1.55, with a volume of 5,700 shares.
Medicure Trading Up 4.0 %
The company has a market cap of C$15.89 million, a P/E ratio of 12.92 and a beta of 1.11. The company has a current ratio of 2.04, a quick ratio of 1.29 and a debt-to-equity ratio of 3.27. The business has a 50 day moving average price of C$1.35 and a 200-day moving average price of C$1.23.
Medicure (CVE:MPH – Get Free Report) last announced its quarterly earnings results on Friday, July 28th. The company reported C$0.02 earnings per share (EPS) for the quarter. Medicure had a return on equity of 10.59% and a net margin of 9.08%. The business had revenue of C$5.99 million during the quarter. Analysts forecast that Medicure Inc. will post 0.111276 earnings per share for the current fiscal year.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.
Featured Articles
- Five stocks we like better than Medicure
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Is Enbridge Stock Too Cheap to Pass Up Now?
- Overbought Stocks Explained: Should You Trade Them?
- 5 Best REIT Alternatives for Passive Real Estate Income
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 5 Reasons Kroger Should Be On Every Income Investor Watchlist
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.